| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | KIN001-260 | GDSC1000 | pan-cancer | AAC | 0.22 | 4e-13 |
| mRNA | dexamethasone | CTRPv2 | pan-cancer | AAC | -0.22 | 6e-11 |
| mRNA | ruxolitinib | CTRPv2 | pan-cancer | AAC | 0.15 | 4e-05 |
| mRNA | sirolimus:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.13 | 0.0001 |
| mRNA | CAL-101 | GDSC1000 | pan-cancer | AAC | 0.12 | 0.0002 |
| mRNA | MK-2206 | CTRPv2 | pan-cancer | AAC | -0.14 | 0.0002 |
| mRNA | Rapamycin | CTRPv2 | pan-cancer | AAC | -0.13 | 0.0002 |
| mRNA | ML239 | CTRPv2 | pan-cancer | AAC | 0.13 | 0.0004 |
| mRNA | temsirolimus | CTRPv2 | pan-cancer | AAC | -0.17 | 0.0005 |
| mRNA | Cerulenin | CTRPv2 | pan-cancer | AAC | -0.12 | 0.0006 |